Literature DB >> 15936218

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.

Jian-An Yao1, Xiaoyi Du, Daniel Lu, Robert L Baker, Eric Daharsh, Philip Atterson.   

Abstract

INTRODUCTION: The HERG channel is widely used for the assessment of proarrhythmic risk for new drugs. HERG channel blockers obstruct channel functions through various mechanisms, which usually show time dependence, voltage dependence, and state dependence. The voltage protocol and temperature may affect the estimation of drug potency, but limited information is available in this regard. The purpose of this study was to evaluate the influence of voltage protocol and temperature on predicting the potency of HERG channel blockers, and to determine electrophysiological approaches for new drugs screening studies.
METHOD: Whole-cell patch-clamp electrophysiology was carried out by utilizing different voltage step protocols to examine the potency of compounds known to preferentially block the channel in the closed (ketoconazole and BeKm-1), open, and/or inactivated states (E-4031, astemizole, and terfenadine) in HEK293 cells transfected with HERG cDNA at room temperature and near-physiological temperature.
RESULTS: Drug potency determined using different voltage protocols varied dependent on the mechanisms of drug actions. For most compounds, the IC(50) values obtained with a long pulse step protocol at room temperature were close to those determined with the voltage protocols designed to disclose their intrinsic potency. Relative to room temperature, the potency of E-4031, terfenadine, and ketoconazole was not changed at approximately 35 degrees C, but potency of astemizole was reduced. DISCUSSION: The long pulse step protocol with room temperature can be selected for HERG channel safety screening studies. Alternative voltage protocols or temperatures should be considered if HERG study results are not consistent with other cardiac safety assessments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936218     DOI: 10.1016/j.vascn.2005.04.008

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  21 in total

1.  Transfer of rolf S3-S4 linker to HERG eliminates activation gating but spares inactivation.

Authors:  Frank S Choveau; Aziza El Harchi; Nicolas Rodriguez; Bénédicte Louérat-Oriou; Isabelle Baró; Sophie Demolombe; Flavien Charpentier; Gildas Loussouarn
Journal:  Biophys J       Date:  2009-09-02       Impact factor: 4.033

2.  Effects of Temperature on Heteromeric Kv11.1a/1b and Kv11.3 Channels.

Authors:  Maike Mauerhöfer; Christiane K Bauer
Journal:  Biophys J       Date:  2016-08-09       Impact factor: 4.033

3.  Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

Authors:  Xi-Ping Huang; Thomas Mangano; Sandy Hufeisen; Vincent Setola; Bryan L Roth
Journal:  Assay Drug Dev Technol       Date:  2010-12       Impact factor: 1.738

4.  Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.

Authors:  Gea-Ny Tseng; Kailas D Sonawane; Yuliya V Korolkova; Mei Zhang; Jie Liu; Eugene V Grishin; H Robert Guy
Journal:  Biophys J       Date:  2007-02-09       Impact factor: 4.033

5.  Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.

Authors:  H Takemasa; T Nagatomo; H Abe; K Kawakami; T Igarashi; T Tsurugi; N Kabashima; M Tamura; M Okazaki; B P Delisle; C T January; Y Otsuji
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 6.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

7.  Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.

Authors:  V F S Dubois; E Casarotto; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2016-09-07       Impact factor: 8.739

8.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.

Authors:  Ari J Alexandrou; Rona S Duncan; Anneli Sullivan; Jules C Hancox; Derek J Leishman; Harry J Witchel; Joanne L Leaney
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

9.  Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome.

Authors:  Ahmad S Amin; Lucas J Herfst; Brian P Delisle; Christine A Klemens; Martin B Rook; Connie R Bezzina; Heather A S Underkofler; Katherine M Holzem; Jan M Ruijter; Hanno L Tan; Craig T January; Arthur A M Wilde
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

10.  Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.

Authors:  Aziza El Harchi; Dario Melgari; Yi Hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.